Business
Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that Nature Medicine (IF: 58.7) has published the results of the Phase 1 clinical study of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarci
About this update from Innovent Biologics, Inc.
[{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that Nature Medicine (IF: 58.7) has published the results of the Phase 1 clinical study of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma[Link]. Publication in this leading international academic journal indicates the strong recognition of the therapy's clinical potential and marks another significant milestone in China's progress in developing novel anti-tumor medications. Based on the study findings, a multi-regional Phase 3 clinical trial (G-HOPE-001, NCT06238843) was launched in 2024 to further evaluate IBI343 as a safe and effective treatment option for patients with advanced G/GEJ AC.","length":1055,"tagName":"p"},{"type":"text","content":"Gastric cancer remains one of the most common malignant tumors in the world. According to the GLOBOCAN 2022 statistics, it ranks as the fifth most common malignant tumor and the fifth leading cause of cancer-related death globally, with an estimated 970,000 new cases and 660,000 deaths annually. Each year, China reports 359,000 new cases and 260,000 deaths from gastric cancer, representing 37.0% and 39.4% of global totals, respectively, highlighting a significant unmet medical need.","length":487,"tagName":"p"},{"type":"text","content":"CLDN 18.2 is a tight junction protein expressed in differentiated epithelial cells on the gastric mucosa under normal physiological conditions. Previous studies have revealed that Claudin18.2 is highly expressed in multiple types of cancer, including gastric cancer (60-80%), pancreatic cancer (50%), esophageal carcinoma (30-50%), and lung cancer (40-60%). Targeting CLDN18.2 with monoclonal antibodies (mAbs) and ADCs represents a promising new approach for treating gastric cancer.","length":484,"tagName":"p"},{"type":"text","content":"This published study is a global, multicenter Phase 1 clinical trial (ClinicalTrial.gov identifier: NCT05458219) designed to evaluate the safety, tolerability and preliminary ...